Abstract: This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide.
Abstract: This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide.
Abstract: This invention provides stable, lyophilized formulations of canfosfamide as well as the methods of preparation of those stable lyophilized formulations.
Abstract: Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides and their salts are tubulin polymerization inhibitors, useful in the treatment of cancer.
Type:
Grant
Filed:
February 9, 2010
Date of Patent:
April 2, 2013
Assignee:
Telik, Inc.
Inventors:
Paul P. Beroza, Komath V. Damodaran, Stella Lui, Wenli Ma, Zhuo Wang, Hua Xu
Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
Type:
Grant
Filed:
September 27, 2011
Date of Patent:
January 29, 2013
Assignee:
Telik, Inc.
Inventors:
Robert T. Lum, Stephan D. Parent, Chunsheng Qiao, Steven R. Schow
Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
Type:
Grant
Filed:
March 23, 2012
Date of Patent:
December 18, 2012
Assignee:
Telik, Inc.
Inventors:
William A. Boulanger, Steven J. Collier, Stephen A. Eastham, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Hans J. Kjaersgaard, Harold Meckler, Robert E. Polomski, Steven R. Schow, Pavel E. Zhichkin
Abstract: This invention provides stable, lyophilized formulations of canfosfamide as well as the methods of preparation of those stable lyophilized formulations.
Abstract: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.
Abstract: A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.
Type:
Grant
Filed:
October 15, 2007
Date of Patent:
June 26, 2012
Assignee:
Telik, Inc.
Inventors:
Gail L. Brown, James G. Keck, Michael M. Wick
Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
Type:
Grant
Filed:
December 21, 2004
Date of Patent:
June 12, 2012
Assignee:
Telik, Inc.
Inventors:
William A. Boulanger, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Harold Meckler, Steven R. Schow, Pavel E. Zhichkin
Abstract: Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides and their salts are tubulin polymerization inhibitors, useful in the treatment of cancer.
Type:
Application
Filed:
February 9, 2010
Publication date:
April 26, 2012
Applicant:
TELIK INC.
Inventors:
Paul P. Beroza, Komath V. Damodaran, Stella Lui, Wenli Ma, Zhuo Wang, Hua Xu
Abstract: 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.
Type:
Grant
Filed:
September 25, 2009
Date of Patent:
March 6, 2012
Assignee:
Telik, Inc.
Inventors:
Natalia Aurrecoechea, Paul P. Beroza, Komath V. Damodaran, Karen Y. Pontius, Louise Robinson, Reyna J. Simon, Truong Vu, Kevin T. Weber
Abstract: Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.
Type:
Grant
Filed:
July 17, 2007
Date of Patent:
January 10, 2012
Assignee:
Telik, Inc.
Inventors:
David R. Allen, Wenli Ma, Brian T. Peterson, Louise Robinson, Steven R. Schow, Songyuan Shi, Reyna J. Simon, Kevin T. Weber, Michael M. Wick
Abstract: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates and their salts, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer and autoimmune diseases, alone and in combination with other therapies.
Type:
Grant
Filed:
December 12, 2007
Date of Patent:
January 18, 2011
Assignee:
Telik, Inc.
Inventors:
Edgardo Laborde, Andrew B. Kelson, Wenli Ma, Kevin T. Weber
Abstract: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N,N?,N?-tetrakis(2-chloroethyl)-phosphorodiamidates, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.
Type:
Grant
Filed:
November 29, 2006
Date of Patent:
February 2, 2010
Assignee:
Telik, Inc.
Inventors:
Wenli Ma, Kevin T. Weber, Robert M. Yee
Abstract: Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.
Inventors:
Edgardo Laborde, Louise Robinson, Fanying Meng, Brian T. Peterson, Hugo O. Villar, Steven E. Anuskiewicz, Yoshiro Ishiwata, Shoji Yokochi, Yukiharu Matsumoto, Takuji Kakigami, Hideaki Inagaki, Takahito Jomori, Kouji Matsushima
Abstract: Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula wherein each A is independently a proton-accepting substituent; each R is independently a noninterfering substituent; n is 0, 1, or 2; and each linker is independently an isostere of —NHCONH— or of —N?N— or of —NHCO—. Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.
Type:
Grant
Filed:
June 23, 2005
Date of Patent:
October 2, 2007
Assignee:
Telik, Inc.
Inventors:
Richard Sportsman, Hugo O. Villar, Lawrence M Kauvar, Wayne R Spevak